Background G-protein-coupled receptors(GPRs) are the largest family of membrane proteins in the human genome, positively involving in human physiological and metabolic activities. Drugs targeted to GPRs have developed fast. However, there are still few GPR-targeted drugs for cancer treatment. GPR183, an orphan seven-transmembrane receptor, have been widely studied in immune regulation. Yet, its role in tumor immunity remains mysterious.Results In our study, we performed a pan-cancer analysis of GPR183. Though statistically significantly differed between tumor and normal samples in various cancers, the expression of GPR183 showed a dual trend. Besides, we applied integrated network analysis to predict GPR183 related genes and analyzed their function with GO and Pathway analysis. GPR183 was strongly associated with immune responses. Moreover, we evaluated the prognostic value of GPR183 in various cancers and found it related to the prognosis of BRCA, SKCM, LUSC, LGG and UVM. We further explore its immunoregulatory function based on differentially expressed genes. Finally, we estimated the tumor immune infiltration associated with GPR183 expression using “TIMER”. The GPR183 expression was highly correlation with macrophages and dendritic cells infiltration.Conclusions GRP183 showed a multiple immunoregulatory role in tumor progression. GPR183 was related to prognosis of five cancer types(BRCA, SKCM, LUSC, LGG and UVM). We also found GPR183 had intimate connection to PD-1 signals. GPR183 might become a potential therapeutic target for cancer treatment.